Both IL-12R and IL-23R have been demonstrated to signal via JAK2; JAK2 deficient donor T cells or JAK2 inhibition with pacritinib were demonstrated to significantly alleviate GVHD in murine models via spared Treg differentiation and reductions in Th1 and Th17 differentiation in in mouse and human T cells (144). The gene discussed is JAK2; the disease is graft versus host disease.